Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.

International journal of cancer - 1 Jul 2026

Fan Xiaoxiao, Wei Chenxi, Rong Minjun, Wang Shengnan, Wang Jiaying, Wang Xiaohan, Han Xiao, Meng Xue

Abstract excerpt

PD-L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene-positive tumors remains unclear. This study analyzed 273 patients with stage IV non-small cell lung cancer harboring driver gene mutations. All patients had PD-L1 expression levels ≥10%. The effect of PD-L1 expression on progression-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Oncogenes

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41872688
DOI: 10.1002/ijc.70413
PMCID: PMC13140019

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.PMID 41872688Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.Semantic proximity Read ↗

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Semantic proximity Read ↗

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity Read ↗

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Semantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read ↗

Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.